Abstract
FLT3 internal tandem duplications (FLT3-ITDs) are present in nearly 25% of patients with AML and have been associated with poor response to conventional therapy and poor outcome. We retrospectively evaluated the effect of reinforced courses of chemotherapy on the prognostic value of FLT3-ITDs in 159 AML patients prospectively enrolled in the ALFA-9000 trial, which randomly compared three reinforced induction regimens (standard 3+7 including high-dose daunorubicin, double induction, and timed-sequential therapy). FLT3-ITD was present in 40/159 (25%) blast samples and associated with high WBC (P = 0.002) and cytogenetics (P < 0.001) with a higher incidence (35%) in patients with a normal karyotype. There was no difference in CR rate between FLT3-wt and FLT3-ITD patients (80% vs 78%). Relapse-free survival (RFS) was similar in both groups (5-year RFS, 33% vs 32%; P = 0.41), even after adjustment for age, sex, WBC, cytogenetics, and treatment arm. A trend to a worse survival was observed in the FLT3-ITD group (estimated 5-year OS, 23% vs 37%; P = 0.09), mainly in patients with a normal karyotype. This was associated with a dramatic outcome in relapsing FLT3-ITD patients (estimated 3-year post-relapse survival, 0% vs 27%; P = 0.04). These results suggest that the bad prognosis associated with FLT3-ITDs in AML might be partly overcome using reinforced chemotherapy. Early detection of FLT3 mutations might thus be useful to intensify induction as well as post-remission therapy in FLT3-ITD patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Matthews W, Jordan CT, Wiegand GW, Pardoll D, Lemischka IR . A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations Cell 1991 65: 1143–1152
Rosnet O, Schiff C, Pebusque MJ, Marchetto S, Tonnelle C, Toiron Y, Birg F, Birnbaum D . Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells Blood 1993 82: 1110–1119
Small D, Levenstein M, Kim EK, Carow C, Amin S, Rockwell P, Witte L, Burrow C, Ratajczak M, Gewirtz AM, Civin CI . STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells Proc Natl Acad Sci USA 1994 91: 459–463
Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, Sonoda Y, Fujimoto T, Misawa S . Internal tandem duplication of the flt3 gene found in acute myeloid leukemia Leukemia 1996 10: 1911–1918
Yokota S, Kiyoi H, Nakao M, Iwai T, Misawa S, Okuda T, Sonoda Y, Abe T, Kahsima K, Matsuo Y, Naoe T . Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines Leukemia 1997 11: 1605–1609
Xu F, Taki T, Yang HW, Hanada R, Hongo T, Ohnishi H, Kobayashi M, Bessho F, Yanagisawa M, Hayashi Y . Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children Br J Haematol 1999 105: 155–162
Xu F, Taki T, Eguchi M, Kamada N, Ishii E, Endo M, Hayashi Y . Tandem duplication of the FLT3 gene is infrequent in infant acute leukemia. Japan Infant Leukemia Study Group Leukemia 2000 14: 945–947
Kiyoi H, Naoe T, Yokota S, Nakao M, Minami S, Kuriyama K, Takeshita A, Saito K, Hasegawa S, Shimodaira S, Tamura J, Shimazaki C, Matsue K, Kobayashi H, Arima N, Suzuki R, Morishita H, Saito H, Ueda R, Ohno R . Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho) Leukemia 1997 11: 1447–1452
Abu-Duhier FM, Goodeve AC, Wilson GA, Care RS, Peake IR, Reilly JT . Genomic structure of human FLT3: implications for mutational analysis Br J Haematol 2001 113: 1076–1077
Kiyoi H, Towatari M, Yokota S, Hamaguchi M, Ohno R, Saito H, Naoe T . Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product Leukemia 1998 12: 1333–1337
Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Muller C, Gruning W, Kratz-Albers K, Serve S, Steur C, Buchner T, Kienast J, Kanakura Y, Berdel WE, Serve H . Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways Blood 2000 96: 3907–3914
Rombouts WJ, Blokland I, Lowenberg B, Ploemacher RE . Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene Leukemia 2000 14: 675–683
Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Saito H, Ueda R, Ohno R, Naoe T . Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies Blood 2001 97: 2434–2439
Abu-Duhier FM, Goodeve AC, Wilson GA, Care RS, Peake IR, Reilly JT . Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia Br J Haematol 2001 113: 983–988
Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, Asou N, Kuriyama K, Jinnai I, Shimazaki C, Akiyama H, Saito K, Oh H, Motoji T, Omoto E, Saito H, Ohno R, Ueda R . Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia Blood 1999 93: 3074–3080
Iwai T, Yokota S, Nakao M, Okamoto T, Taniwaki M, Onodera N, Watanabe A, Kikuta A, Tanaka A, Asami K, Sekine I, Mugishima H, Nishimura Y, Koizumi S, Horikoshi Y, Mimaya J, Ohta S, Nishikawa K, Iwai A, Shimokawa T, Nakayama M, Kawakami K, Gushiken T, Hyakuna N, Katano N, Tsurusawa M, Fujimoto T . Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia. The Children's Cancer and Leukemia Study Group, Japan Leukemia 1999 13: 38–43
Kondo M, Horibe K, Takahashi Y, Matsumoto K, Fukuda M, Inaba J, Kato K, Kojima S, Matsuyama T . Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia Med Pediatr Oncol 1999 33: 525–529
Abu-Duhier FM, Goodeve AC, Wilson GA, Gari MA, Peake IR, Rees DC, Vandenberghe EA, Winship PR, Reilly JT . FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group Br J Haematol 2000 111: 190–195
Meshinchi S, Woods WG, Stirewalt DL, Sweetser DA, Buckley JD, Tjoa TK, Bernstein ID, Radich JP . Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia Blood 2001 97: 89–94
Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, Willman CL, Radich JP . FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia Blood 2001 97: 3589–3595
Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, Walker H, Wheatley K, Bowen DT, Burnett AK, Goldstone AH, Linch DC . The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials Blood 2001 98: 1752–1759
Castaigne S, Archimbaud E, Bordessoule D, Fenaux P, Tilly H, de Revel T, Simon M, Janvier M, Renoux M, Grobois B, Dupriez B, Zini J, Tertian G, Legros M, Chastang C, Degos L . Sequential induction or double induction chemotherapy increase disease free survival compared to ‘3+7’ chemotherapy in less than 50 years adults with acute myeloid leukemia Blood 1996 88: 291a
Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, Brunning R, Gale RP, Grever MR, Keating MJ . Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia J Clin Oncol 1990 8: 813–819
Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA, Arthur DC, Mayer RJ . Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype Cancer Res 1998 58: 4173–4179
Kaplan E, Meier P . Nonparametric estimation from incomplete observations J Am Stat Assoc 1958 53: 457–481
Peto R, Peto J . Asymptotically efficienr rank invariant test procedures J R Stat Soc 1972 135: 185–206
Cox D . Regression models and life-tables J R Stat Soc 1972 34: 187–220
Whitman SP, Archer KJ, Feng L, Baldus C, Becknell B, Carlson BD, Carroll AJ, Mrozek K, Vardiman JW, George SL, Kolitz JE, Larson RA, Bloomfield CD, Caligiuri MA . Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study Cancer Res 2001 61: 7233–7239
Schnittger S, Schoch C, Kern W, Staib P, Wuchter C, Sauerland M, Serve H, Buechner T, Haferlach T, Hiddeman W . FLT3 length mutations in AML: correlation to cytogenetics, FAB-subtype, and prognosis in 652 patients Blood 2000 96: 826a
Schnittger S, Schoch C, Kern W et al. FLT3 length mutations and MLL-duplications in AML: correlation to cytogenetics, FAB-subtype and prognosis Ann Hematol 2001 80: S11
Fröhling S, Breitruck J, Schlenk R, Kreitmeier S, Tobis K, Döhner H, Döhner K . FLT3 internal tandem duplications and survival in adult acute myeloid leukemia: analysis of 188 intensively treated patients Blood 2001 98: 717a
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Boissel, N., Cayuela, J., Preudhomme, C. et al. Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia 16, 1699–1704 (2002). https://doi.org/10.1038/sj.leu.2402622
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402622
Keywords
This article is cited by
-
Frugal alignment-free identification of FLT3-internal tandem duplications with FiLT3r
BMC Bioinformatics (2022)
-
The evolving concept of indications for allogeneic hematopoietic cell transplantation during first complete remission of acute myeloid leukemia
Bone Marrow Transplantation (2021)
-
Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia
Cancer Chemotherapy and Pharmacology (2021)
-
IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen
Scientific Reports (2021)
-
Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports
Clinical Drug Investigation (2020)